Hologic (NASDAQ:HOLX) Receives “Outperform” Rating from Raymond James

Raymond James restated their outperform rating on shares of Hologic (NASDAQ:HOLX) in a research note published on Thursday morning,Benzinga reports. Raymond James currently has a $90.00 price target on the medical equipment provider’s stock, down from their previous price target of $95.00.

Several other research analysts also recently weighed in on the company. BNP Paribas upgraded Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. William Blair reiterated an “outperform” rating on shares of Hologic in a report on Thursday. Wolfe Research initiated coverage on Hologic in a research note on Friday, December 13th. They set a “peer perform” rating on the stock. Morgan Stanley lowered their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, Royal Bank of Canada reduced their price target on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research report on Thursday. Ten analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $85.77.

Hologic Stock Down 10.1 %

HOLX stock opened at $65.45 on Thursday. The company has a market cap of $14.77 billion, a price-to-earnings ratio of 19.65, a price-to-earnings-growth ratio of 2.35 and a beta of 0.98. The company has a fifty day moving average price of $72.63 and a 200 day moving average price of $77.86. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. Hologic has a 12 month low of $64.87 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. Sell-side analysts expect that Hologic will post 4.28 earnings per share for the current year.

Insider Buying and Selling

In other news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.88% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Hologic

Several hedge funds have recently bought and sold shares of HOLX. State Street Corp grew its stake in Hologic by 0.8% in the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock valued at $847,944,000 after acquiring an additional 81,057 shares during the period. FMR LLC lifted its holdings in shares of Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after purchasing an additional 2,174,093 shares in the last quarter. Victory Capital Management Inc. increased its stake in Hologic by 0.5% during the 4th quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock worth $354,506,000 after purchasing an additional 24,358 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Hologic by 0.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock worth $208,051,000 after buying an additional 18,774 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Hologic by 8.6% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider’s stock valued at $200,952,000 after buying an additional 195,285 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.